RxDoctor Payments DataLook up a doctor →

Laura Romundstad

Adult Health · Birmingham, ALNPI 1255757209

Payments from drug & device makers

$10,185in general payments, 2019–2025

Across 456 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$851
  • Novartis$737
  • Merck$529
  • Takeda Pharmaceuticals U.S.A., Inc.$507
  • Incyte Corporation$491
  • plus $6K from 51 others

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$1,329
Johnson & Johnson39$851
Novartis41$737
Merck22$529
Takeda Pharmaceuticals U.S.A., Inc.22$507
Incyte Corporation21$491
AstraZeneca(2 entities)24$442
Genentech USA, Inc.27$442
Bristol Myers Squibb21$388
Pfizer25$375
Daiichi Sankyo Inc.9$234
E.r. Squibb & Sons, L.L.C.13$227
Lilly USA, LLC12$220
Bayer10$205
GSK11$194
Beone Medicines USA, Inc.10$176
Exelixis Inc.7$175
CSL Behring6$172
Sobi, Inc8$163
Regeneron Healthcare Solutions, Inc.8$155
Eisai Inc.9$153
Ipsen Biopharmaceuticals, Inc6$137
Array Biopharma Inc7$123
Deciphera Pharmaceuticals Inc.6$117
Stemline Therapeutics Inc.5$116
AVEO Pharmaceuticals, Inc.5$107
Beigene USA, Inc.5$107
Astellas Pharma US Inc5$96
Seagen Inc.5$90
Gilead(2 entities)5$89
Boehringer Ingelheim4$84
Pharmaessentia USA Corporation3$75
Genmab U.S., Inc.4$75
Pharmacosmos Therapeutics Inc.3$72
Blueprint Medicines Corporation3$72
Sumitomo Pharma America, Inc.3$53
Mirati Therapeutics, Inc.3$51
Adaptive Biotechnologies Corporation3$49
Puma Biotechnology, Inc.2$46
Servier Pharmaceuticals LLC2$43
Coherus Oncology, Inc.2$42
Rigel Pharmaceuticals, Inc.2$33
Iovance Biotherapeutics, Inc.2$32
EMD Serono, Inc.1$31
Karyopharm Therapeutics Inc.1$29
Jazz Pharmaceuticals Inc.1$28
Sanofi1$25
Recordati_rare_diseases_inc.1$25
Acrotech Biopharma Inc.1$24
Morphosys, US Inc.1$23
Kyowa Kirin, Inc.1$22
Immunogen, Inc.1$20
Apellis Pharmaceuticals, Inc.1$19
ADC Therapeutics America, Inc.1$17
Fennec Pharmaceuticals, Inc.1$17
Taiho Oncology, Inc.1$16
Agios Pharmaceuticals, Inc.1$14

How this compares

$10,185 in reported general payments places this provider in the 95th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama →

Medicare billing

Part B allowed, 2024
$137,511
Medicare patients
183
Services billed
5,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult health in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →